PBZ-SR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jul 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PBZ-SR is an extended-release oral small-molecule tablet approved in 1956 by Novartis with an unknown mechanism of action and indication profile. The product's mechanism of action and therapeutic indication cannot be determined from available data.
LOE Approaching
With LOE approaching, the brand team is likely consolidating and preparing for generic competition; hiring is minimal and focused on defensive positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and approaching loss of exclusivity, PBZ-SR offers limited career acceleration. Roles available are defensive and focused on revenue maintenance rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on PBZ-SR at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.